Seres <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Positive Phase 1b Data for SER-155 in Reducing Bloodstream Infections in Allogeneic Stem Cell Transplant Patients, Plans Phase 2 Trial
Seres Therapeutics Inc. announced that new post hoc data from its SER-155 Phase 1b trial will be presented at IDWeek 2025, scheduled for October 19-22 in Atlanta, Georgia. The oral presentation will cover clinical and microbiological outcomes of bloodstream infections (BSI) in adults undergoing allogeneic hematopoietic stem cell transplant, based on results from a randomized, double-blind, placebo-controlled study. According to the company, SER-155 was associated with a 77% reduction in BSIs, as well as lowered systemic antibiotic use and rates of febrile neutropenia compared to placebo. The presentation, which will include data on BSI pathogens, clinical outcomes, prophylaxis, and antimicrobial resistance patterns, is set for October 20. Seres Therapeutics is finalizing plans for a Phase 2 study of SER-155 following feedback from the FDA.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Seres Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9544542-en) on October 14, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。